Second primary malignancies after treatment for malignant lymphoma

To determine the incidence and possible causes of second primary malignancies after treatment for Hodgkin’s and Non-Hodgkin’s lymphoma (HL and NHL), a cohort of 3764 consecutive patients diagnosed with HL or NHL between January 1970 and July 2001 was identified using the Sheffield Lymphoma Group database. A search was undertaken for all patients diagnosed with a subsequent primary malignancy. Two matched controls were identified for each case. Odds ratios were calculated to detect and quantify any risk factors in the cases compared to their matched controls. Mean follow-up for the cohort was 5.2 years. A total of 68 patients who developed second cancers at least 6 months after their primary diagnosis were identified, giving a crude incidence of 1.89% overall: 3.21% among the patients treated for HL, 1.32% in those treated for NHL. Most common were bronchial, breast, colorectal and haematological malignancies. High stage at diagnosis almost reached statistical significance in the analysis of just the NHL patients (odds ratio = 3.48; P = 0.068) after adjustment for other factors. Treatment modality was not statistically significant in any analysis.

High stage at diagnosis of NHL may be a risk factor for developing a second primary cancer.

Keywords: second primary cancer; malignant lymphoma; matched case–control study

‘Late effects’ of lymphoma treatment are being increasingly documented as more patients are surviving their disease. Arguably the most serious of these late effects is the development of a second primary malignancy (SPM).

An association between HL and other tumours was first documented in 1957 (Moertal and Hagedorn, 1957) when a combined review and case series of 120 patients was published. Since then, numerous studies have described a significantly increased risk of second cancers in these patients. Initially, the major risk was thought to be from second acute leukemias (Canellos et al, 1975; Pederson-Bjergaard and Larsen, 1982; Valagussa et al, 1986) and associations were quickly demonstrated with certain chemotherapy regimens such as MOPP (mustine, Oncovin, procarbazine, prednisone) (Valagussa et al, 1986; Kaldor et al, 1990; Tura et al, 1993). Splenectomy has also been proposed as a risk factor (Pederson-Bjergaard and Larsen, 1982). The risk of developing acute leukemia appears to peak approximately 5 years after onset of chemotherapy (Tura et al, 1993) and plateau by approximately 10 years (Tucker et al, 1988). In contrast, the risk of second solid cancers appears to increase with time from diagnosis (Valagussa et al, 1986; Tucker et al, 1988; Swerdlow et al, 1992), which means that they, in fact, are the major risk to long-term survivors of HL. Much controversy exists as to the major risk factors for developing second solid cancers, with many investigators finding an increased risk in all treatment groups (Tucker et al, 1988; Boivin et al, 1995; Dores et al, 2002). However, that there is an increased risk with younger age (Swerdlow et al, 2000) and particularly of breast cancer in women treated with radiotherapy (RT) is now widely accepted (Janjan et al, 1988; Hancock et al, 1993; van Leeuwen et al, 1994a; Aisenberg et al, 1997).

Noticeably, less literature exists concerning second cancers in patients treated for NHL. This may, in part, be a reflection of the higher average age at diagnosis, the poorer survival and hence the reduced availability of patients for long-term follow-up. However, a significant risk of myelodysplasia and acute leukaemia has been demonstrated in patients treated with a variety of treatment regimens such as radiotherapy alone and high-dose chemotherapy with autologous stem cell support (Stone, 1994; Micaleff et al, 2000). An excess risk of developing certain solid cancers has also been described, particularly bladder, kidney, lung, malignant melanoma, HL (Travis et al, 1991) and brain tumours (Travis et al, 1993). Of these, a positive association was demonstrated between chemotherapy and bladder cancer (Travis et al, 1993), and between radiotherapy and lung, bladder and bone malignancies (Travis et al, 1991). However, other studies have failed to demonstrate any excess risk of these tumours in any treatment groups. A study published in 1990 (Lavey et al, 1990) described an incidence of second solid tumours similar to that expected in the general population, with significant differences only present for salivary gland tumours (both overall and in patients treated with chemotherapy alone) and malignant melanomas (overall).

Where an elevated risk of solid cancers has been demonstrated, it appears to remain significantly increased up to 20 years after lymphoma diagnosis (Travis et al, 1993). While it is important to determine the incidence of second primary malignancies in survivors of both HL and NHL, it is more...
vital to define the risk factors for each type of malignancy, so that either these can be modified or patients at particular risk can be closely monitored.

PATIENTS AND METHODS

The study was a nested case–control design. In total, 3764 consecutive patients diagnosed with HL or NHL between the January 1970 and 28 July 2001 were identified using the Sheffield Lymphoma Group database. For all patients, information on sex, date of birth, age at diagnosis, date of diagnosis, histology, stage at diagnosis, presenting site, date last seen, vital status, duration of follow-up, duration of second cancers was extracted from the database. Patients who were only seen once at Weston Park Hospital and completed all of their treatment elsewhere were immediately excluded from the study. For the purpose of this study, SPM is defined as any site of second malignancy either 

in situ or invasive, except Kaposis’s Sarcoma in HIV positive individuals, diagnosed at least six complete months after lymphoma diagnosis but before death. Any cases of SPM diagnosed in patients who received initial treatment for their lymphoma at other centres were excluded, as were all malignancies diagnosed within 6 months of lymphoma diagnosis and also cases of third primary malignancies.

Two controls were identified for every case, matched as closely as possible for their primary diagnosis (HL or NHL), sex, age at diagnosis (± 2 years), duration of follow-up (± 1 year of diagnosis from primary diagnosis to the second cancer diagnosis), and year of diagnosis (± 10 years). The group of second cancer cases and their matched controls is the main study sample. For both the cases and their controls, additional information was extracted from their notes on the type and dates of treatment received, including chemotherapy regimens, radiotherapy doses and fields, splenectomy, stem cell support, and also date and diagnosis of the subsequent primary malignancy. Information was also sought as to the smoking status of the patients, but this was often (> 35%) incomplete.

Matched conditional logistic regression (Breslow and Day, 1980) was used to determine whether any of the variables were risk factors for the development of an SPM. Three separate groups of analyses were undertaken (either HL or NHL disease as the first primary malignancy), one based only on NHL patients and finally one based only on the HL patients. Since matching was performed on age, sex, whether HD or NHL disease as the first primary disease and the duration of follow-up, none of these variables, or those derived from them, were included in the analyses. However, because matching on time of diagnosis was only performed within 10 years, in these analyses, adjustment for the effect of time of diagnosis was performed by including it as a covariate in the model. Thus, the variables decade of primary diagnosis (1970–1979, 1980–1989, 1990–2001), presenting site (nodular disease, extra-nodular disease, other (B symptoms (4), cord compression (1), superior vena cava obstruction (1) and alcohol pain (1)), stage (low: I and II; high: III and IV) and treatment (radiotherapy only, chemotherapy only, radiotherapy and chemotherapy, surgery alone/unknown treatment/no treatment) were included in all three analyses. Additionally, for the NHL patients, histology type for NHL (high grade: high-grade B cell or high-grade T cell; other: low-grade B cell, low-grade T cell or unknown grade) was also analysed. For the analysis of the HL patients, histology type for HL (nodular-sclerosis; mixed cell; other: lymphocyte depleted, lymphocyte predominant or unknown) and having a splenectomy or not were included. The groups for classifying histology for both HL and NHL were necessary due to the small numbers in some of the groups. Odds ratios (OR), 95% confidence intervals (CI) and P-values were estimated when the variables were examined separately in univariate models and all together in multivariate models. Odds ratios were not presented when there were fewer than 5% of either cases or controls in the risk factor level. All analyses were performed in Stata version 7.0 (StataCorp, 2001).

RESULTS

In total, 3764 consecutive patients diagnosed with HL or NHL between the January 1970 and 28 July 2001 were identified using the Sheffield Lymphoma Group database. For the whole population, the median duration of follow-up is 2.79 years, mean 5.19 years. There were 174 patients who were only seen once at Weston Park Hospital and completed all of their treatment elsewhere who were immediately excluded from the study. Figure 1 gives the details of the remaining 3590 patients, as well as shows why 25 of the 93 cases of second malignancies identified were excluded from the analysis. Therefore, 68 cases of SPM met the inclusion criteria, giving a crude incidence of 1.89% overall: 3.21% among the patients treated for HL, 1.32% in those treated for NHL. Most common were bronchial, breast, colorectal and haematological malignancies. All SPMs included in the study are shown in Table 1. Thus, matched conditional logistic regression was performed on 68 cases (35 HD, 33 NHL) and 136 controls to determine whether any of the variables were risk factors for the development of an SPM.

All patients

When the matched conditional logistic regression was performed on the 68 cases and 136 controls together, only decade of diagnosis ($P = 0.029$) was significant in both the univariate and multivariate models (Table 2). Patients diagnosed in 1980–1989 had half the risk of developing an SPM than patients diagnosed in 1970–1979. Similarly, patients diagnosed in 1990–2001 had less than a tenth of the risk of developing an SPM than patients diagnosed in 1970–1979 in the multivariate model. Patients diagnosed with either stage III or IV disease had a higher risk of developing an SPM (1.7 times) than those diagnosed with stage I or II disease, and those patients given chemotherapy, either alone or in combination had lower risks of developing an SPM than those patients just having radiotherapy, although none of these were statistically significant.

NHL patients

The analysis of the NHL patients only showed that patients with high stage disease had 3.5 times the risk of developing an SPM than those diagnosed with low stage disease although this was marginally nonsignificant after adjustment for other factors in the multivariate model ($P = 0.068$). Patients with NHL that was not high grade had a lower but nonsignificant risk of developing SPM than those with high grade NHL, and patients given chemotherapy alone or in combination generally had a lower risk than those given only radiotherapy, but these were not significant (Table 3).

Hodgkin’s lymphoma patients only

Table 4 presents the univariate and multivariate results for the matched conditional logistic regression for the 35 and 70 HL cases and controls, respectively. None of the variables reached statistical significance for predicting whether the patient would develop an SPM for those patients diagnosed with HL, in either the univariate or multivariate models.

DISCUSSION

There can be no doubt that the long-term survivors of malignant lymphoma are at increased risk of developing second cancers and
that this risk results mainly from the oncogenic sequelae of cytotoxic and/or radiation therapy (Connors, 2003; Hancock, 2003). It was surprising that we could not replicate these results, although due to the low numbers (four cases, seven controls) in the minimal treatment (no chemotherapy and/or radiotherapy) group the reference category for the analyses of treatment was generally taken as those patients having radiotherapy alone. It is quite difficult to assess the actual risks (Henry-Amar, 2000) but is likely that incidence of leukaemia in the first 10 years after chemotherapy for HL is in the order of 5–10% (with a relative risk exceeding 10, compared with a matched reference population). Similar relative risks are seen for secondary NHL 5–15 years post-treatment. However, these conditions have a low natural incidence so the actual number of cases is small. More seriously, for both HL and NHL, the incidence of second solid tumours approaches 20% after two decades (with a relative risk of only between 1.5 and 2.5, but accounting for larger number of cases). Many of the earlier reports were from specialist centres or clinical trial collaborators leading inevitably to patient selection. Our study deals with a relatively nonselected series of consecutive patients seen at a provincial lymphoma centre.

All lymphomas

Of the 68 SPMs identified in this study, bronchial and breast carcinomas were most frequent, and solid cancers overall were much more common than haematological malignancies. This is supported by similar findings in a 1990 study of second malignancy risk after lymphoma treatment (Moertal and Hagendorn, 1957).

Conditional logistic regression analysis showed a nonstatistically significant increase in the risk of developing an SPM for those with higher stage tumours. The observed increase in the risk of developing an SPM for those diagnosed in the decade 1970–1979 compared with those diagnosed in 1980–1989 and 1990–2001 is almost certainly an artefact of the design with matching having been performed on length of follow-up. The patients first diagnosed in 1970–1979 had a longer follow-up time in which to develop a second primary compared to the later decades, and are

---

**Table 1** Distribution of SPMs by lymphoma diagnosis and sex

| Type of SPM                        | HL male | HL female | NHL male | NHL female | Total |
|-----------------------------------|---------|-----------|----------|------------|-------|
| Bronchial carcinoma               | 4       | 2         | 5        | 2          | 13    |
| Breast carcinoma                  | 0       | 7         | 0        | 4          | 11    |
| Colorectal carcinoma              | 1       | 0         | 4        | 3          | 8     |
| Skin cancers                      | 4       | 0         | 3        | 1          | 8     |
| Leukaemia or myelodysplasia       | 4       | 2         | 1        | 0          | 7     |
| Stomach carcinoma                 | 0       | 1         | 3        | 0          | 4     |
| Multiple myeloma                  | 1       | 0         | 0        | 1          | 2     |
| Prostate carcinoma                | 0       | 2         | 0        | 2          | 2     |
| Brain tumours                     | 1       | 0         | 1        | 0          | 2     |
| Pancreatic carcinoma              | 1       | 0         | 1        | 0          | 2     |
| Metastatic carcinoma, unknown primary | 1     | 0         | 1        | 0          | 2     |
| NHL                               | 1       | 1         | 0        | 0          | 2     |
| Bladder carcinoma                 | 1       | 0         | 0        | 0          | 1     |
| Cholangiocarcinoma                | 1       | 0         | 0        | 0          | 1     |
| Ovarian carcinoma                 | 0       | 1         | 0        | 0          | 1     |
| Cardiac sarcoma                   | 0       | 1         | 0        | 0          | 1     |
| Anal carcinoma                    | 0       | 0         | 0        | 1          | 1     |
| Total                             | 20      | 15        | 21       | 12         | 68    |

SPM = second primary malignancy.

---

Figure 1 Total population, exclusions and distribution of cases and controls within the study sample.
Table 2  Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for risk factors for both HL and NHL patients together

| Factor                      | Category* | All patients univariate OR (95% CI) ca 68, co 136 | All patients multivariate OR (95% CI) |
|-----------------------------|-----------|--------------------------------------------------|--------------------------------------|
| Decade of diagnosis (years) | 1970–1979 | 1.00                                              | 1.00                                 |
|                            |           | 30, 50                                            | 30, 50                               |
|                            | 1980–1989 | 0.50 (0.18–1.39)                                  | 0.55 (0.19–1.60)                     |
|                            |           | 28, 57                                            | 28, 57                               |
|                            | 1990–1999 | 0.08ab (0.01–0.75)                                | 0.09c (0.01–0.94)                    |
|                            |           | 10, 29                                            | 10, 29                               |
| Stage at diagnosis         | Low       | 1.00                                              | 1.00                                 |
|                            |           | 43, 91                                            | 43, 91                               |
|                            | High      | 1.29 (0.72–2.32)                                  | 1.69 (0.72–3.95)                     |
|                            |           | 25, 40                                            | 25, 40                               |
| Presenting site at diagnosis | Nodal disease | 1.00                                              | 1.00                                 |
|                            |           | 54, 94                                            | 54, 94                               |
|                            | Extra-nodal disease | 0.56 (0.25–1.27)                                  | 0.69 (0.26–1.85)                     |
|                            |           | 13, 36                                            | 13, 36                               |
|                            | Other     | —                                                 | —                                    |
|                            |           | 1, 6                                              | 1, 6                                 |
| Treatment given            | RT only   | 1.00                                              | 1.00                                 |
|                            |           | 31, 54                                            | 31, 54                               |
|                            | CT only   | 0.87 (0.43–1.75)                                  | 0.63 (0.23–1.68)                     |
|                            |           | 19, 38                                            | 19, 38                               |
|                            | RT and CT | 0.62 (0.28–1.39)                                  | 0.63 (0.26–1.50)                     |
|                            |           | 14, 37                                            | 14, 37                               |
|                            | Surgery only/no treatment/treatment u/k | 0.99 (0.26–3.84) | 1.05 (0.21–5.15) |
|                            |           | 4, 7                                              | 4, 7                                 |

*Reference category stated first. abP ≤ 0.029. cP ≤ 0.044. —, Odds ratio not presented as fewer than 5% of either cases or controls in the risk factor level.

Table 3  Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for risk factors for NHL patients only

| Factor                      | Category* | NHL patients univariate OR (95% CI) ca 33, co 66 | NHL patients multivariate OR (95% CI) |
|-----------------------------|-----------|--------------------------------------------------|--------------------------------------|
| Decade of diagnosis (years) | 1970–1979 | 1.00                                              | 1.00                                 |
|                            |           | 6, 10                                             | 6, 10                                |
|                            | 1980–1989 | 0.65 (0.13–3.16)                                  | 0.86 (0.15–4.86)                     |
|                            |           | 17, 32                                            | 17, 32                               |
|                            | 1990–1999 | 0.16 (0.01–2.60)                                  | 0.22 (0.01, 4.04)                    |
|                            |           | 10, 24                                            | 10, 24                               |
| Stage at diagnosis         | Low       | 1.00                                              | 1.00                                 |
|                            |           | 17, 44                                            | 17, 44                               |
|                            | High      | 2.28 (0.97–5.36)                                  | 3.48 (0.91–13.26)                    |
|                            |           | 16, 17                                            | 16, 17                               |
| Presenting site at diagnosis | Nodal disease | 1.00                                              | 1.00                                 |
|                            |           | 20, 32                                            | 20, 32                               |
|                            | Extra-nodal disease | 0.62 (0.26–1.43)                                  | 1.09 (0.34–3.53)                     |
|                            |           | 13, 34                                            | 13, 34                               |
|                            | Other     | —                                                 | —                                    |
|                            |           | 0, 0                                              | 0, 0                                 |
| Treatment given            | RT only   | 1.00                                              | 1.00                                 |
|                            |           | 13, 26                                            | 13, 26                               |
|                            | CT only   | 1.30 (0.50–3.37)                                  | 0.56 (0.15–2.16)                     |
|                            |           | 12, 18                                            | 12, 18                               |
|                            | RT and CT | 0.64 (0.19–2.18)                                  | 0.50 (0.11–2.29)                     |
|                            |           | 5, 15                                             | 5, 15                                |
|                            | Surgery only/no treatment/treatment u/k | 0.92 (0.20–4.14) | 0.63 (0.10–3.99) |
|                            |           | 3, 7                                              | 3, 7                                 |
| Histology                  | High grade NHL | 1.00                                              | 1.00                                 |
|                            |           | 16, 30                                            | 16, 30                               |
|                            | Other NHL | 0.89 (0.39–2.04)                                  | 0.70 (0.25–1.98)                     |
|                            |           | 17, 36                                            | 17, 36                               |

*Reference category stated first. —, odds ratio not presented as fewer than 5% of either cases or controls in the risk factor level.
likely to have had more controls diagnosed in the later periods. This is therefore of no particular interest.

**Non-Hodgkin’s lymphoma**

The incidence of SPMs in this study population is less than has been reported in previous studies and this is especially marked in the NHL patients, in whom a crude incidence of 1.32% is reported here, compared to the 4.22% (Travis *et al*, 1991) to 8.77% (Travis *et al*, 1993) reported in the literature in both small studies (Lavey *et al*, 1990) and large multicentre analyses (Travis *et al*, 1991). This may be a reflection of the short duration of follow-up overall for both HL and NHL patients in this study (mean 5.19 years, median 2.79 years) compared to a median of 5.5 years (Lavey *et al*, 1990), or mean of 7.4 years (Travis *et al*, 1993) in other studies, but the possibility that not all cases of SPM have been recorded on the database cannot be excluded. A simple way of increasing the mean duration of follow-up and the overall incidence would be to limit the cohort to patients who survived longer than 6 months. This would give a more accurate representation of the incidence, as patients who have died within 6 months have not actually had the chance to develop an SPM, by this study’s definition. Additionally, the initial determination of those developing an SPM was performed only 6 months after the cutoff for inclusion in the whole cohort thus reducing the mean follow-up time. Finally, 145 of the 3764 patients were lost to follow-up, and so may have in fact developed an SPM that is not known about. These patients comprised those who were followed-up at other hospitals, those who went on to receive some of their treatment at local district general hospitals and those who were discharged from clinic but whose General Practitioners did not return the two-yearly postal follow-up requests.

There was only a single case of leukaemia that occurred in this patient group, which is probably significantly lower than the 11 out of 517 patients with leukaemia or myelodysplasia reported in a 1983 study (Greene *et al*, 1983), or the four out of 61 patients reported in 1996 (Travis *et al*, 1996), although we would need the duration of follow-up for each of the studies to be comparable to be certain of this. However, in the former study, the high incidence is probably due to the intensity of the treatment received by the patients; seven out of the nine patients had had radical radiotherapy and one had six cycles of MOPP chemotherapy, in contrast to our study population, who had received treatment as diverse as node excision only and through to intense combined modality regimens, thus making comparison difficult.

| Table 4 | Odds ratios (OR), 95% confidence intervals (CI) and numbers of exposed cases (ca) and controls (co) for risk factors for HL patients only |
|---|---|---|---|
| Factor | Category* | HL patients univariate OR (95% CI) ca 35, co 70 | HL patients multivariate OR (95% CI) |
| Decade of diagnosis (years) | 1970–1979 | 1.00 | 1.00 |
| | 1980–1989 | 0.45 (0.11 –1.78) 21. 25 | 0.31 (0.06, 1.56) |
| | 1990–1999 | — 0.5 | — |
| Stage at diagnosis | Low | 1.00 | 1.00 |
| | High | 0.73 (0.31 –1.73) 9. 23 | 1.26 (0.33–4.74) |
| Presenting site at diagnosis | Nodal disease | 1.00 | 1.00 |
| | Extra-nodal disease | — 0.2 | — |
| | Other | — 1. 6 | — |
| Treatment given | RT only | 1.00 | 1.00 |
| | CT only | 0.53 (0.18 –1.55) 7. 20 | 0.66 (0.13–3.28) |
| | RT and CT | 0.65 (0.22–1.95) 9. 22 | 0.55 (0.16–1.89) |
| Surgery only/no treatment/treatment u/k | — | — |
| Histology | Nodular sclerosing | 1.00 | 1.00 |
| | Mixed cell | 0.73 (0.29 –1.87) 14. 30 | 0.69 (0.25–1.88) |
| | Other HL | 0.63 (0.22–1.80) 8. 20 | 0.65 (0.22–1.95) |
| Splenectomy | No | 1.00 | 1.00 |
| | Yes | 1.48 (0.57–3.79) 12. 19 | 1.51 (0.50–4.56) |

*Reference category stated first. —, odds ratio not presented as fewer than 5% of either cases or controls in the risk factor level.
Solid tumours were far more common in our patients, with the most frequently observed SPM being bronchial carcinoma. This supports the findings of a 1991 multi-centre study (Travis et al, 1991), which reported 274 cases of lung cancer (more than any other site) in 29,153 patients treated for NHL. The same study found colorectal carcinomas to be the next most frequent (186 cases), followed by breast and prostate cancers. Skin cancers had been excluded from the analysis. In the current study, breast carcinoma and skin cancers were common, but only two cases of prostate cancer were recorded. Similar findings were also published in 1993 (Travis et al, 1993), where the investigators reported bronchial carcinoma as the most common SPM, followed by colorectal, breast and prostate carcinomas.

From the matched conditional logistic regression analysis, the one variable that almost reached statistical significance was stage at diagnosis, which was only marginally nonsignificant (P = 0.068), with patients of stages III and IV at higher risk of developing an SPM compared to those presenting with either stage I or II disease. This result could prove to be an independent risk factor in a larger study, but may also have been confounded by the fact that stage I and II disease is most likely to be treated with local radiotherapy, whereas stage III and IV disease is more likely to have been treated with combination chemotherapy for high-grade disease or prolonged chlorambucil + radiotherapy for low-grade disease. Previous studies have shown positive correlates between radiotherapy dose and leukaemia SPM (Greene et al, 1983), radiotherapy and leukaemia, lung, bladder and bone SPMs, and chemotherapy and leukaemia and bladder SPM (Travis et al, 1991). As the number of patients in this study was small, separate analyses were only carried out for the two most common SPMs, lung and breast, for all lymphomas together, so no comparison to other results can be made. Histological subtype did not reach statistical significance in this study (as a risk factor for developing an SPM). A recent study of patients with mantle cell lymphoma (Barista et al, 2002) reported a crude incidence of 7.05% of patients developing an SPM. Clearly, this is much higher than reported here, but lies within the range reported in the literature, so this sort of lymphoma may not prove to be an independent risk factor.

**Hodgkin’s lymphoma**

The incidence of SPMs in this group (3.21%) is slightly lower than most previously reported (Valagussa et al, 1986; Prior and Pope, 1988; Tucker et al, 1988; Cimino et al, 1991; Swerdlow et al, 1992, 1997; Foss Abrahamsen et al, 1993), but lies within the overall range of 2.17 (Prior and Pope, 1988) to 7.53% (Swerdlow et al, 1997).

Here, six cases of haematological malignancy were recorded (0.55%), which is noticeably lower than the 4.35% (Pederson-Bjergaard and Larsen, 1982) or 4.57% (Tura et al, 1993) reported elsewhere. However, both studies selected patients treated with a combination of MOPP chemotherapy and radiotherapy. More recently, a study in a more heterogeneous population reported an incidence of 2.27% (van Leeuwen et al, 1994b), although clearly still much higher than reported here, is somewhat comparable to this study. As stated previously, it is possible that the reduced incidence reported here is a result of the relatively short duration of follow-up and potentially incomplete records.

Solid cancers were more common than haematological SPMs, as is the case in the literature (Canellos et al, 1975; Valagussa et al, 1986; Prior and Pope, 1988; Tucker et al, 1988; Cimino et al, 1991; Foss Abrahamsen et al, 1993; van Leeuwen et al, 1994a; Boivin et al, 1995; Swerdlow et al, 1997). Here, breast carcinoma was the most common solid SPM, with seven cases (1.66%) recorded. Again, this figure is much lower than the 2.82% (Hancock et al, 1993) or 12.61% (Aisenberg et al, 1997) previously reported. However, in the former study, the mean duration of follow-up was 5.19 years, and in the latter, median 18 years and all patients were aged less than 60 and had stage 1 or 2 disease and so this was also a highly selected patient group. Bronchial carcinoma occurred in six patients, an increased risk has also been previously reported (Kaldor et al, 1990; van Leeuwen et al, 1995; Swerdlow et al, 2001). In the first study of 98 cases and matched controls (Kaldor et al, 1990), the investigators found a higher risk following CT than RT. The second study (van Leeuwen et al, 1995) related radiation dose received by the affected area of lung to risk in their 30 cases and controls. Most recently, in a study of 88 cases out of a cohort of 5519 (Swerdlow et al, 2001), borderline significance was found for MOPP chemotherapy compared to other treatment regimens. In the current study, all six of the cases received mantle RT, and two received CT (either MOPP or L[Leukeran]OPP) for relapse. None of the variables were statistically significant in the conditional logistic regression analyses, although patients who had a splenectomy had a nonsignificantly higher risk of developing an SPM (P = 0.47) in the multivariate model. It is possible that splenectomy would have been statistically significant if we were able to restrict the analysis to leukaemias, as an increased risk has been reported of 21 out of 557 splenectomised patients compared to one out of 145 not splenectomised (P = 0.01) (Tura et al, 1993) but the numbers in our study are too small for such an analysis.

**Bronchial carcinoma SPM**

When additional logistic regression analysis was undertaken on the 13 triples for the patients having an SPM in the lung, there were no statistically significant risk factors, although treatment modality bordered on significance when it was grouped up as the rest vs combination RT and CT (odds ratio: 3.70; 95% CI: 0.72, 18.97; P = 0.12). Treatment modality might well be statistically significant if the sample size allowed valid division into HL and NHL patients, or the treatment modalities did not need to be grouped up. Different treatment modalities have been reported to affect the risk of bronchial carcinoma in patients with HL; although two studies concluded that chemotherapy was the most important risk factor (Kaldor et al, 1990; Swerdlow et al, 2001) the third showed radiation dose to be statistically significant (van Leeuwen et al, 1995).

**Breast carcinoma SPM**

Further logistic regression analysis was carried out on the 11 triples for the cases having an SPM in the lung, there were no statistically significant risk factors, although treatment modality bordered on significance when it was grouped up as the rest vs combination RT and CT (odds ratio: 3.70; 95% CI: 0.72, 18.97; P = 0.12). Treatment modality might well be statistically significant if the sample size allowed valid division into HL and NHL patients, or the treatment modalities did not need to be grouped up. Different treatment modalities have been reported to affect the risk of bronchial carcinoma in patients with HL; although two studies concluded that chemotherapy was the most important risk factor (Kaldor et al, 1990; Swerdlow et al, 2001) the third showed radiation dose to be statistically significant (van Leeuwen et al, 1995).

**CONCLUSION**

In this study of all patients treated in one provincial Centre, having high stage disease at presentation, especially for NHL patients, was only marginally nonsignificant. This may be a significant risk factor in a larger study. Other individual factors may be important for different SPMs and only with larger numbers of patients and longer follow-up can these be elucidated.
REFERENCES

Aisenberg AC, Finkestein DM, Doppke KP, Koerner FC, Boivin J-F, Willett CG (1997) High risk of breast cancer after irradiation of young women with Hodgkin’s disease. Cancer 79(6): 1203 – 1210

Barista I, Cabanillas F, Ramoguera JE, Khouri IF, Yang Y, Smith TL, Strom SS, Medeiros LJ, Hagemeister FB (2002) Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann Oncol 13: 318 – 322

Boivin J-F, Hutchinson GB, Auber AG, Bernstein L, Davis FG, Michel RP, Zanke B, Tan CTC, Fuller LM, Mauch P, Ullmann JE (1995) Incidence of second cancers in patients treated for Hodgkin’s disease. J Natl Cancer Inst 87(10): 32 – 41

Breslow NE, Day NE (1980) Statistical Methods in Cancer Research, Volume 1 – The Analysis of Case–Control Studies. Lyon: IARC Scientific Publication No. 32, International Agency for Research on Cancer

Canellios GP, DeVita VT, Arseneau JC, Whang-Peng J, Johnson REC (1975) Second malignancies complicating Hodgkin’s disease in remission. Lancet 1: 947 – 949

Cimino G, Papa G, Tura P, Mazza P, Rossi Ferrini PL, Bosi A, Amadori S, La Coco F, D’Arcangelo E, Giannarelli D, Mandelli F (1991) Second primary cancer following Hodgkin’s disease: updated results of an Italian multicentric study. J Clin Oncol 9(3): 432 – 437

Connors JM (2003) Hodgkin’s lymphoma: the hazards of success. J Clin Oncol 21: 3431 – 3439

Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm HH, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van’t Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin’s disease: a population-based evaluation over 25 years. J Clin Oncol 15: 3484 – 3494

Foss Abrahamsson J, Anderson A, Hannisdal E, Nome O, Foss Abrahamsson A, Kvaály S, Hest H (1993) Second malignancies after treatment of Hodgkin’s disease: the influence of treatment, follow-up time, and age. J Clin Oncol 11(2): 255 – 261

Greene MH, Young RC, Merrill JM, DeVita VT (1983) Evidence of a treatment dose-response in acute non-lymphoblastic leukemias which occur after therapy of NHL. Cancer Res 43: 1891 – 1898

H Hancock BW (2003) Cancers induced by treatment of lymphoma. Lancet Oncol 4: 577 – 578

H Hancock SL, Tucker MA, Hoppe RT (1993) Breast cancer after treatment of Hodgkin’s disease. J Natl Cancer Inst 85(1): 25 – 31

Henry-Amar M (2000) Long-term problems in malignant lymphoma. In Malignant Lymphoma, Hancock BW, Selby PJ, MacLennan K, Armitage JO (eds) pp 421 – 436. London: Arnold

Janan NA, Wilson JF, Gillin N, Anderson T, Greenberg M, Schewe K, Cox JD (1998) mammary carcinoma developing after radiotherapy and chemotherapy for Hodgkin’s disease. Cancer 61: 252 – 254

Kaldor JM, Day NE, Clarke EA, van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pederson Band P, Assouline D, Koch M, Choo W, Prior P, Blair V, Langmark F, Pompe Kirn V, Neal F, Peters D, Pfeiffer M, Nayon R, van Kerkhoff EHM, van Heerde P, Somers R, Eby NL, Prosnitz LR, Moertal CG, Hallaert KG, Hagenbeek A, Nuytinck M, DeAssigni C (1997) Leukemia or lymphoma and coexistent primary malignant lesions: a review of the literature and a study of 120 cases. Blood 12: 788 – 803

Pederson-Bjgraard J, Larsen SO (1982) Incidence of acute non-lymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin’s disease. N Engl J Med 307(16): 965 – 971

Prior P, Pope DJ (1988) Hodgkin’s disease: subsequent primary cancers in relation to treatment. Br J Cancer 58: 512 – 517

Swerdlow AJ, Barber JA, Horwich A, Cunningham D, Miller P, Ramirez R (1997) Second malignancy in patients with Hodgkin’s disease treated at the royal marsden hospital. Br J Cancer 75(1): 116 – 123

Swerdlow AJ, Barber JA, Vaughan Hudson G, Cunningham D, Bennett MH, MacLennan KA (1992) Risk of second primary cancers after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British national lymphoma investigation. BMJ 304: 1137 – 1143

Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, Lister TA, Rotanti ASZ, Vaughan Hudson G, Williams MV, Linch DC (2001) Lung cancer after Hodgkin’s disease: a nested case–control study of the relation to treatment. J Clin Oncol 19(6): 1610 – 1618

Travis LB, Curtis RE, Boice JD, Hankey BF, Fraumeni JF (1991) Second cancers following non-Hodgkin’s lymphoma. Cancer 7: 2002 – 2009

Travis LB, Curtis RE, Glimelius B, Holowaty E, van Leeuwen FE, Lynch CF, Adami H, Gospodarowicz M, Wacholder F, Inskip P, Tucker MA, Fraumeni JF, Boice JD (1993) Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst 85(23): 1932 – 1937

Travis LB, Weeks J, Curtis RE, Chaffey JT, Stovall M, Banks PM, Boice JD (1996) Leukaemia following low-dose total body irradiation and chemotherapy for non-Hodgkin’s lymphoma. J Clin Oncol 14(2): 563 – 571

Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin’s disease. N Eng J Med 318(2): 76 – 81

Tura S, Fiacchini M, Zinzani PL, Brusamolino E, Gobbi PG (1993) Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin’s disease. J Clin Oncol 11(5): 925 – 930

Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G (1986) Second acute leukemia and other malignancies following treatment for Hodgkin’s disease. J Clin Oncol 4(6): 830 – 837

van Leeuwen FE, Klokman WJ, Hagenbeek A, Nuytinck M, van den Belt-Dusebout AW, van Kerkhoff EHM, van Heerde P, Somers R (1994a) Leukemia risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 12(2): 312 – 325

van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout EHM, Hagenbeek A, Nuytinck M, van Kerkhoff EHM, Pinedo HM, Somers R (1994b) Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with tensiposide combinations, number of episodes o chemotherapy, and bone marrow damage. J Clin Oncol 12(5): 1063 – 1073

van Leeuwen FE, Klockman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Nuytinck M, Boice JD, Burgers MV, Somers R (1995) Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 87: 1530 – 1537